How community pharmacists are reducing heart failure readmissions

Heart failure affects roughly half a million Australians, with the Australian Institute of Health and Welfare placing it among the three leading causes of potentially preventable hospital admissions. Once a patient leaves hospital after a decompensation episode, the risk of returning within thirty days hovers around one in five, climbing higher among those sent home with complex regimens, limited support or fragmented follow-up. The personal cost is measured in lost independence, while the system cost runs into the billions and pressures bed capacity in major hospitals from Perth to Sydney.

Community pharmacists are unusually well placed to interrupt this cycle. They are the health professional most Australians see most often, often without an appointment and sometimes after hours. The Seventh Community Pharmacy Agreement, alongside programs such as Home Medicines Review and MedsCheck, has steadily expanded the clinical scope of the profession, and that access now translates into a genuine safety net for patients negotiating the precarious weeks after discharge.

The weight of heart failure readmissions on the system

Data analysed in the Medical Journal of Australia shows that heart failure accounts for more than 60,000 hospitalisations a year nationally, with about a quarter of those patients returning within a month. Mortality within a year of a first admission still sits close to 25 percent, and readmission itself is a strong predictor of that outcome. In Western Australia and South Australia, where distances to tertiary cardiac centres are substantial, the readmission burden falls disproportionately on older people living alone in regional towns.

These figures matter for pharmacists because the reasons patients come back are often modifiable. Inadequate discharge counselling, poor understanding of dietary sodium targets, unresolved side effects, and undetected deterioration all appear repeatedly in root-cause analyses. The community pharmacy sits at the intersection of these problems, with the dispensing history, the clinical record and the patient relationship all in one place.

Medication adherence as a lever pharmacists can pull

Adherence to the four pillars of guideline-directed heart failure therapy — ACE inhibitors or ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — sits somewhere between 40 and 60 percent in routine Australian practice. Each ten percent drop in adherence is linked to measurable rises in hospitalisation and death. Pharmacists see the refill gaps before anyone else in the system and can act on them quickly.

In a typical Sydney or Melbourne pharmacy, that might mean a quick conversation at the counter when a Webster-pak cycle is overdue, or a call to the patient when the statin repeats but the sacubitril-valsartan does not. A short, structured chat grounded in patient-centred medication management principles can shift a hesitant patient from skipping doses to taking them consistently. The same conversation often surfaces cost barriers, where a quick word about PBS safety net thresholds or 60-day dispensing can ease household pressure.

Home Medicines Review after a hospital stay

The Home Medicines Review program, funded under Medicare and delivered through community pharmacies since 2001, remains one of the quiet successes of Australian primary care. After a GP referral, an accredited pharmacist visits the patient at home, conducts a structured medicines review, and writes back to the GP and community pharmacy with recommendations. For a recently discharged heart failure patient, that visit can resolve confusion about diuretic timing, identify duplications, and surface issues that never made it onto the discharge summary.

Trials in Australia and overseas consistently show that HMR participation is associated with fewer adverse drug events and lower readmission rates. The challenge is timing: reviews need to happen in the first two to three weeks after discharge, when the patient is most vulnerable and most likely to be juggling several new medicines. Programs in Victoria, Queensland and New South Wales are now piloting hospital-initiated referrals, where cardiac nurses or pharmacists can trigger the HMR before the patient even walks out of hospital.

Teaching patients to spot the warning signs early

Self-care is the unglamorous backbone of heart failure management. Daily weighing, watching for ankle swelling, restricting fluid to 1.5 litres a day, and keeping sodium intake under 2 grams are the habits that keep people out of hospital. Heart Foundation Australia publishes plain-language action plans that translate well to the pharmacy setting, where a five-minute conversation can anchor the advice in a patient's daily routine.

Mental wellbeing matters more than the system often acknowledges. Depression and anxiety are common after a heart failure admission, and they undermine adherence, sleep and motivation to attend follow-up. Pharmacists who ask how a patient is really sleeping, and who recognise that sleep quality and anxiety often travel together, can refer on early and slow the drift back into decompensation. A simple prompt to bring the action plan to every GP visit, or to call if weight jumps by two kilograms in three days, has measurable impact.

Working alongside GPs, cardiac nurses and hospital teams

Heart failure care is multidisciplinary by necessity, and pharmacists are increasingly drawn into formal collaborative arrangements. Pharmacist-led heart failure clinics attached to general practices in Adelaide and Brisbane have produced reductions in readmissions comparable to nurse-led models. In Western Sydney, the local health district has piloted shared care plans where the community pharmacist receives a structured handover from the hospital team at discharge.

The practical obstacles are well known. Hospital pharmacists do not always have a direct line to the patient's regular community pharmacy, discharge summaries arrive days after the patient, and My Health Record uptake, while growing, is still patchy across some age groups. Where these gaps close — through secure messaging, agreed handover templates, or local shared-care agreements — the effect on readmissions is visible within months rather than years.

Digital tools, dose administration aids and MedsCheck

Australian pharmacies have invested heavily in digital infrastructure over the past decade. Dose administration aids such as Webster-paks remove the cognitive load of complex regimens and give the pharmacist a clear visual cue when doses are missed. GuildCare, MedAdvisor and similar platforms push reminders to patients, capture intervention notes, and create an audit trail that can be shared with prescribers.

The MedsCheck and Diabetes MedsCheck consultations, while not heart failure specific, give a structure for a focused half-hour review. When a patient has both heart failure and diabetes, the Diabetes MedsCheck becomes a natural opportunity to revisit the SGLT2 inhibitor, the diuretic dose and renal function in one sitting. Electronic prescribing, now mainstream in metropolitan Australia, has cut the lost-script and double-dispensing problems that used to fragment care around discharge.

Reaching patients in rural and remote Australia

The community pharmacist becomes even more critical in rural and remote settings, where the next cardiac outreach clinic may be a fortnight away and the Royal Flying Doctor Service handles the most serious deteriorations. In the Northern Territory, several Aboriginal Community Controlled Health Organisations have partnered with local pharmacies to embed medicines information workers into discharge planning, with promising early results.

Tasmania, parts of country Western Australia and far-west New South Wales all face the same challenge: a thin workforce, long travel times, and patients who sometimes drive past several towns to fill a script. Outreach models that combine telehealth follow-up with local pharmacy touchpoints — a phone call from the hospital pharmacist followed by an in-person catch-up at the country pharmacy — are appearing in state-funded pilots. Pharmacists in these communities often know their patients by name, by family, and by which brand of teabag they prefer, and that relational continuity is itself a clinical asset.

Reducing heart failure readmissions will not come from any single profession, hospital or piece of technology. It will come from the cumulative weight of thousands of small, well-timed actions by people the patient already trusts. The community pharmacist is one of those people, present in every Australian community from the Brisbane CBD to Broome and from Hobart to Darwin. Every script dispensed with a quick check on the action plan, every HMR triggered on the day of discharge, every conversation about sleep or cost or side effects, is a chance to keep a patient at home where they want to be. The infrastructure is in place, the evidence is robust, and the next patient through the door is often the one who needs that attention most.